Ghafary Ismail, Seoud Talal, Jorgensen Michael, Marhaba Jade, Briggs William M, Jamorabo Daniel S
Gastroenterology and Hepatology, University of Connecticut School of Medicine, Farmington, USA.
Gastroenterology and Hepatology, University of Florida, Gainesville, USA.
Cureus. 2024 Nov 19;16(11):e74043. doi: 10.7759/cureus.74043. eCollection 2024 Nov.
Background The utility of small bowel capsule endoscopy (SBCE) in the inpatient setting is controversial due to retention rates and costs. Aim This study aims to evaluate whether using SBCE significantly improved the identification of potential bleeding sites or reduced the risk of 30-day readmission for overt or occult gastrointestinal bleeding. Methods This was a single-center retrospective cohort study involving inpatients who underwent SBCE at a suburban tertiary care hospital from January 1, 2012, to January 1, 2022, for suspected small bowel bleeding. There was no control group used in this observational study. We used chi-square testing to determine the significance among our categorical variables and t-tests to compare means for our numerical variables. We also did multivariable logistic regression to analyze risk factors for increased hospital stay. All statistical analysis was done in R (R Core Team, 2020, R Foundation for Statistical Computing, Vienna, Austria). Results We identified 514 inpatients who underwent SBCE from January 1, 2012, to January 1, 2022, including 300 (58.4%) men and 214 (41.6%) women. Most (305/514, 59.3%) had no notable findings on SBCE, but 209/514 (40.7%) subsequently underwent endoscopic procedures, and a bleeding site was identified and treated in 168/209 (80.4%). Undergoing a subsequent procedure significantly increased the average number of days between capsule deployment and discharge (9.6 vs. 4.9 days, p < 0.005) without significantly reducing the risk for 30-day readmission (OR 1.33, 95% CI 0.9-1.9, p = 0.2). Among the 209 patients who had a subsequent procedure, identifying and treating a bleeding site did not significantly change readmission rates (OR 1.35, 95% CI 0.6-3.1, p = 0.5) compared to patients who did not have a procedure. Conclusion We did not find that inpatient SBCE significantly affected 30-day readmission rates even if an endoscopic procedure was subsequently done or a potential bleeding site was treated.
由于滞留率和成本问题,小肠胶囊内镜检查(SBCE)在住院患者中的应用存在争议。
本研究旨在评估使用SBCE是否能显著提高潜在出血部位的识别率或降低因显性或隐性胃肠道出血导致30天再入院的风险。
这是一项单中心回顾性队列研究,纳入了2012年1月1日至2022年1月1日在一家郊区三级护理医院因疑似小肠出血而接受SBCE的住院患者。本观察性研究未设对照组。我们使用卡方检验来确定分类变量之间的显著性,并使用t检验来比较数值变量的均值。我们还进行了多变量逻辑回归分析以分析住院时间延长的风险因素。所有统计分析均在R软件中完成(R核心团队,2020年,R统计计算基金会,奥地利维也纳)。
我们确定了2012年1月1日至2022年1月1日期间接受SBCE的514例住院患者,其中男性300例(58.4%),女性214例(41.6%)。大多数患者(305/514,59.3%)在SBCE检查中未发现明显异常,但209/514例(40.7%)随后接受了内镜检查,其中168/209例(80.4%)发现并治疗了出血部位。接受后续检查显著增加了胶囊置入至出院之间的平均天数(9.6天对4.9天,p<0.005),但并未显著降低30天再入院的风险(OR 1.33,95%CI 0.9 - 1.9,p = 0.2)。在209例接受后续检查的患者中,与未接受检查的患者相比,发现并治疗出血部位并未显著改变再入院率(OR 1.35,95%CI 0.6 - 3.1,p = 0.5)。
我们发现即使随后进行了内镜检查或治疗了潜在出血部位,住院患者的SBCE也未显著影响30天再入院率。